Research and Markets (http://www.researchandmarkets.com/research/72532e/thailand_pharmaceu) has announced the addition of the "Thailand Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
The Thailand Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Thailand's pharmaceuticals and healthcare industry
For the Q4 2009 update of the Thailand Pharmaceuticals & Healthcare Report, we have extended our forecasts for prescription pharmaceuticals, patented products, generic drugs and over-the-counter (OTC) medicines through to 2018. The South East Asian country's US$3.52bn pharmaceutical market is projected to post a compound annual growth rate (CAGR) of 8.20% in local currency terms. Due to the strengthening of the baht over the next 10 years, the market will post a CAGR of 10.37% in US dollar terms. However, we must caution that there are significant risks to this optimistic forecast, primarily political instability.
In the Pharmaceutical Environment Ratings table for Q409, Thailand has improved by one position, from 10th to 9th, out of the 15 key markets surveyed in the Asia Pacific region. Thailand's growing and ageing population represents a substantial commercial opportunity for drugmakers, although its controversial compulsory licensing scheme is deterring foreign investment.
Thailand's reputation for over-medicating has been highlighted once again. During the swine flu outbreak in July 2009, it was announced that the country would import second-line antivirals, such as zanamivir, amantadine and rimantadine. These would be in addition to oseltamivir, which was increasingly associated with resistance to the H1N1 virus in other parts of the world. In the World Health Organization (WHO)'s study on oseltamivir resistance during the 2007-2008 flu season, Thailand was named as one of the countries with a high antiviral drug resistance rate.